The French National Agency for the Safety of Medicines and Health Products (ANSM) has authorised FineHeart to commence a ...

The Hybrid Heart, a soft robotic total artificial heart, offers a breakthrough in treating end-stage heart failure with ...

Nat Clin Pract Cardiovasc Med. 2006;3(7):346-347. Since the first widespread clinical application of left ventricular assist devices (LVADs) for patients with end-stage heart failure in the ...

FineHeart announced today that French regulators gave it the green light to initiate a first-in-human heart device trial in ...

The HeartMate II is currently the only continuous-flow left-ventricular assist device (LVAD) approved by the FDA for both bridge-to-transplantation and destination therapy. Because of its ...

The device was successfully implanted in 10 patients ... of which one was segmented to direct capture of the LBB and four to left ventricular septal pacing, according to the presentation.

EBR Systems announced that it received commitments for a fully underwritten institutional placement to raise $36.1 million ...